| Revenue growth | 19% YoY for FY26; ₹4,316 million total revenue. |
|---|---|
| Margins | Gross margin normalized to 56% from elevated 63% in FY25. |
| Demand visibility | Strong for flagship hybrids Sanket and Jumbo; maize growing rapidly. |
| Management confidence | High; focusing on 'under-commit and over-perform' strategy. |
Growth
Revenue grew 19% YoY; PAT stood at ₹384M (9% margin). Cotton-paddy portfolio contributed 58% of revenue.
Outlook
FY27 revenue guidance of 15-20% growth. Targeted international revenue share of 10-15% within five years.
Risks
Erratic monsoons (El Nino) and China export restrictions impacting plant nutrition segment (-18%).
Earnings Call filed with BSE, NSE: NATHBIOGEN. Summary written with AI assistance from the document.
Nath Bio-Genes (India) Ltd: key numbers
- Share price
- ₹136.87
- Market cap
- ₹260.1 Cr
- Revenue (annual)
- ₹445.1 Cr
- Net profit (annual)
- ₹41.63 Cr
- P/E (TTM)
- 7.1×Sector 28.6×
- Promoter holding
- 45.60%+0.00% QoQ
- FII holding
- 0.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nath Bio-Genes (India) Ltd
All →Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd held its 33rd AGM on September 24, 2026. Shareholders approved all five resolutions, including a final dividend of ₹2/- per share.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd issued notice for its 33rd Annual General Meeting, to be held on September 24, 2026, alongside the Annual Report for FY2025-26.
Nath Bio-Genes (India) ED Probe / Tax Survey
SEBI has initiated a forensic audit of Nath Bio-Genes (India) Ltd for financial years 2020-21 to 2025-26. CNK & Associates LLP has been appointed as the forensic auditor.
- Execution
- FY 2020-21 to 2025-26
Nath Bio-Genes (India) Investor Presentation: Key Takeaways
Nath Bio-Genes reported strong Q1 FY27 results with Revenue and EBITDA growing 15% and 17% YoY respectively. The company continues to focus on high-yield cotton, maize, and paddy seeds.
Nath Bio-Genes (India) Q1 FY27 Results: Net Profit ₹32.3 Cr, Up 14.1% YoY
Nath Bio-Genes (India) Ltd reported revenue from operations of ₹328.4 Cr (+15.8% YoY) and net profit of ₹32.3 Cr (+14.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹32.3 Cr · +14.1% YoY
Nath Bio-Genes (India) Other Announcement
Nath Bio-Genes (India) Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b). This disclosure provides the updated distribution of shareholding across various investor categories.